The present invention pertains to a medicament for preventing or treating nociceptive pain and/or visceral pain, the medicament comprising as an active ingredient a compound having a P2X4 receptor antagonistic action, or a pharmaceutically acceptable salt thereof.
Provided is a biochemical reaction substrate which can achieve higher test sensitivity and shorter testing time in an allergy test, which can also reduce a required amount of blood or the like needed as a specimen and decrease the number of test steps, thereby facilitating performance of the test, and which is to be used in an allergy test in which infection risk of the test staff is reduced. A biochemical reaction substrate, including: a reaction plate; an absorber; a reaction plate storing portion for storing the reaction plate; an absorber storing portion for storing the absorber; a storage container having a heated portion; and a cover assembled to the storage container so as to cover at least a part of the reaction plate and the absorber stored in the storage container, wherein the reaction plate includes a reaction area in which a specific binding substance that specifically reacts with a substance to be tested in a specimen is immobilized, and a flow passage that connects the absorber and the reaction area, and wherein the cover includes an injection hole for injecting a specimen or the like into the reaction plate.
G01N 35/00 - Automatic analysis not limited to methods or materials provided for in any single one of groups Handling materials therefor
G01N 35/02 - Automatic analysis not limited to methods or materials provided for in any single one of groups Handling materials therefor using a plurality of sample containers moved by a conveyor system past one or more treatment or analysis stations
A diazepine derivative represented by formula (I), where R1 and R2 represent hydrogen, or R1 and R2 bind together to form a naphthalene ring and the like together with the benzene ring to which they bind, R3, R4, R5, R6, and R7 each represents hydrogen, X represents C, CH or N, Y represents N, NH or C(═O), provided that when X is N, Y is not N or NH, and when X is C or CH, Y is not C(═O), Z represents oxygen or sulfur, A represents benzene ring and the like, B represents NHC(═O) and the like, D and E each represents an atomic bond, G represents benzene which may be substituted, and m represents an integer of 0 to 5) or a pharmacologically acceptable salt thereof, and a P2X4 receptor antagonist.
A diazepine derivative represented by formula (I), where R1 and R2 represent hydrogen, or R1 and R2 bind together to form a naphthalene ring and the like together with the benzene ring to which they bind, R3, R4, R5, R6, and R7 each represents hydrogen, X represents C, CH or N, Y represents N, NH or C(═O), provided that when X is N, Y is not N or NH, and when X is C or CH, Y is not C(═O), Z represents oxygen or sulfur, A represents benzene ring and the like, B represents NHC(═O) and the like, D and E each represents an atomic bond, G represents benzene which may be substituted, and m represents an integer of 0 to 5) or a pharmacologically acceptable salt thereof, and a P2X4 receptor antagonist.
C07D 243/10 - Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
A method for therapeutic treatment of pain-associated anxiety or depression in a mammalian subject in need thereof, that includes administering to the subject an effective amount of a pharmaceutical composition containing a morphinan derivative that exhibits an opioid δ receptor agonist activity.
[Problem] To provide a spirocyclic morphinan derivative having an agonist activity against κ-opioid receptor. [Solution] The present invention provides a compound represented by general formula (I) or a pharmaceutically acceptable salt. (In the formula, R13-61-61-6 alkyl group, or the like; R2and R31-61-6 alkyl group, or the like; R4and R51-61-6 alkyl group, or the like; R6represents a hydrogen atom, a hydroxy group, or the like; R7and R81-61-6 alkyl group, or the like, or R7and R8together represent one oxygen atom and are ether-bonded to each other to form an epoxy ring; R9and R101-61-6 alkyl group, or the like, or R9and R103-71-61-6 cyclic ketal; R11and R12are the same or different and each represents a hydrogen atom or a hydroxy group, or R11and R12taken together represent a carbonyl group or a thiocarbonyl group, or R11and R123-71-61-6 cyclic ketal; R133-71-61-62-61-63-73-7 saturated hydrocarbon ring, a saturated heterocycle, or the like.)
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/5386 - 1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 11/00 - Drugs for disorders of the respiratory system
C07D 489/09 - Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems
C07D 491/22 - Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups , , or in which the condensed system contains four or more hetero rings
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
7.
PHARMACEUTICAL FOR TREATING OR PREVENTING CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
Inventor
Uta Daisuke
Hashimoto Satoshi
Nakamura Hideki
Kunigami Toshihiro
Abstract
Provided is a pharmaceutical composition for treating or preventing peripheral neuropathy induced by a chemotherapeutic agent, the pharmaceutical composition containing an alkalinizing agent. Administration of this pharmaceutical composition enables the treatment or prevention of peripheral neuropathy induced by a chemotherapeutic agent, especially a chemotherapeutic agent for cancer. Also provided is an anticancer pharmaceutical composition containing an alkalinizing agent and a chemotherapeutic agent for cancer, by which the expression of peripheral neuropathy is suppressed. Administration of this pharmaceutical composition enables cancer treatment with suppressed expression of peripheral neuropathy.
Provided is a pharmaceutical composition for treating or preventing peripheral neuropathy, the pharmaceutical composition containing an alkalinizing agent. Administration of this pharmaceutical composition enables the treatment or prevention of some lesion, disease, etc., especially diabetic peripheral neuropathy. Also provided is an alkalinizing agent or a pharmaceutical composition containing an alkalinizing agent, by which the expression of peripheral neuropathy is suppressed. Administration of this pharmaceutical composition enables the suppression of expression of peripheral neuropathy.
The present invention provides a solid dispersion comprising a compound represented by general formula (I) or (II) or a pharmacologically acceptable salt thereof.
A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Provided is a composition for increasing muscle mass in a mammal, the composition including citric acid, a salt of citric acid, a hydrate thereof, or a mixture thereof.
The present invention provides a pharmaceutical composition for the treatment or prevention of stress-related disorders, stress-induced anxiety disorders, or stress-related disorders or anxiety disorders associated with depression, the composition containing a selective δ-opioid receptor agonist as an active component, wherein the selective δ-opioid receptor agonist preferably also has a μ-opioid receptor antagonist action and a κ-opioid receptor antagonist action.
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
There is provided a method for producing a composition containing a pharmaceutically acceptable salt of citric acid, a hydrate thereof, or a mixture thereof and having a moisture content of 4.0% by mass or less, the method including irradiating a composition containing a pharmaceutically acceptable salt of citric acid, a hydrate thereof, or a mixture thereof with microwaves.
School Juridical Person Higashi-Nippon-Gakuen (Japan)
The University of Tokyo (Japan)
Nippon Chemiphar Co., Ltd. (Japan)
Inventor
Hiraoka, Miki
Okamoto, Ken
Hirano, Masuharu
Abstract
Provided is a pharmaceutical composition for enhancing intracellular ATP, including a compound represented by General Formula (I)
Provided is a pharmaceutical composition for enhancing intracellular ATP, including a compound represented by General Formula (I)
wherein R1 represents an unsubstituted or substituted phenyl group, R2 represents a cyano group or a nitro group, R3 represents a hydrogen atom or a hydroxyl group, X represents an oxygen atom or —S(O)n—, n represents an integer of 0 to 2, and Y represents an oxygen atom or a sulfur atom, or a pharmaceutically acceptable salt thereof.
Provided is a method which is for preparing a morphinan derivative having a diaryl ether skeleton represented by general formula (III) (In the formula, R1 represents a hydrogen atom, etc., R2, R3, and R4 are the same or different and each represent a hydrogen atom, or an arbitrary substituent, etc., R5 represent a hydrogen atom, a hydroxy group, etc., R14 and R15 are the same or different and each represent a hydrogen atom, or an arbitrary substituent, etc.), and in which a phenyl group is introduced into the 4-position phenol of a morphinan derivative through the Ullmann reaction of a system using a monovalent copper compound or a novel catalytic system simultaneously using a monovalent copper compound and zero-valent metallic copper.
Provided is a method which is for preparing a morphinan derivative having a diaryl ether skeleton represented by general formula (III) (In the formula, R1 represents a hydrogen atom, etc., R2, R3, and R4 are the same or different and each represent a hydrogen atom, or an arbitrary substituent, etc., R5 represent a hydrogen atom, a hydroxy group, etc., R14 and R15 are the same or different and each represent a hydrogen atom, or an arbitrary substituent, etc.), and in which a phenyl group is introduced into the 4-position phenol of a morphinan derivative through the Ullmann reaction of a system using a monovalent copper compound or a novel catalytic system simultaneously using a monovalent copper compound and zero-valent metallic copper.
The present invention relates to a pharmaceutical composition for preventing, suppressing, or treating the symptoms that accompany pseudo-allergic reactions, said pharmaceutical composition comprising, as an active ingredient, a compound having a P2X4 receptor antagonist action or a pharmaceutically acceptable salt of this compound.
A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
A61P 1/06 - Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
A61P 1/08 - Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigoAntiemetics
To provide a medicine useful for protecting renal function or reducing a dietary acid load on the kidney in mammals, particularly humans. Provided is a pharmaceutical composition containing citric acid, a pharmaceutically acceptable salt of citric acid, a hydrate of citric acid, a hydrate of the pharmaceutically acceptable salt of citric acid, or a mixture thereof. Administration of the present pharmaceutical composition makes it possible to protect renal function or reduce a dietary acid load on the kidney.
The present invention relates to a pharmaceutical composition for preventing, suppressing, or treating a symptom associated with an allergic reaction, the pharmaceutical composition including a compound having a P2X4 receptor antagonizing action or a pharmaceutically acceptable salt thereof as an active ingredient.
NATIONAL UNIVERSITY CORPORATION TOTTORI UNIVERSITY (Japan)
NIPPON CHEMIPHAR CO., LTD. (Japan)
Inventor
Taniguchi Fumiaki
Nakamura Kazuomi
Nagata Hiroki
Imai Toshiyasu
Abstract
The present invention pertains to a prophylactic, therapeutic or inhibitory agent for endometriosis, adenomyosis or dysmenorrhea, said prophylactic, therapeutic or inhibitory agent including a compound having a P2X4 receptor antagonistic action, or a pharmaceutically-acceptable salt thereof, as an effective ingredient.
A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
A61P 15/00 - Drugs for genital or sexual disordersContraceptives
A61P 43/00 - Drugs for specific purposes, not provided for in groups
A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
The present invention pertains to a medicament for preventing or treating cough, including, as an active ingredient, a compound having P2X4 receptor antagonistic action, a tautomer, stereoisomer, or pharmaceutically acceptable salt of the compound, or a hydrate or solvate thereof.
C07D 243/10 - Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
A morphinan derivative represented by the following general formula (I):
A morphinan derivative represented by the following general formula (I):
A morphinan derivative represented by the following general formula (I):
wherein R1 represents hydrogen, C1-10 alkyl, cycloalkylalkyl where the cycloalkyl moiety has 3 to 6 carbon atoms, and the alkylene moiety has 1 to 5 carbon atoms, etc.; R2 represents heterocyclic ring containing 1 to 4 heteroatoms selected from N, O and S and at least one carbon atom as ring-constituting atoms, containing at least one set of adjacent ring-constituting atoms bound by a double bond, and further substituted with at least one oxo group; Y binds to a carbon atom as a ring-constituting atom of R2; R3, R4, and R5 represent hydrogen, hydroxy, etc.; R6a and R6b represent hydrogen, etc.; R7 and R8 represent hydrogen, etc.; R9 and R10, which are the same or different, represent hydrogen, etc.; X represents O or CH2; and Y represents C(═O)); a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof is used as an anxiolytic drug, antidepressant, etc.
The present invention pertains to medicament for use in preventing or treating irritable bowel syndrome or inflammatory bowel disease, the medicament comprising as an active ingredient a compound having a P2X4 receptor antagonistic action, or a pharmaceutically acceptable salt thereof.
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
A61P 1/06 - Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
Provided is a useful pharmaceutical composition that exhibits effects of improving sleep quality, relieving stress, and reducing fatigue feeling in a mammal (for example, a human) target by ingestion or administration of a composition containing at least one substance selected from the group consisting of citric acid and a salt thereof.
The present invention provides a compound having a selective opioid δ receptor agonist effect. The present invention provides a pyrazolomorphinan derivative represented by general formula (1) (in the formula, (II) R1 represents a hydrogen atom, an alkyl group, a cycloalkylmethyl group, or the like, R2 represents a hydrogen atom or a hydroxy protecting group, R3 represents a hydroxy group, an alkyl group, a partially unsaturated heterocyclic group, an aryl group, a heteroaryl group, or the like; and R4 represents a hydrogen atom, an alkyl group, an aralkyl group, a cycloalkyl group, a cycloalkyl alkyl group, a saturated heterocyclic group, an aryl group, a heteroaryl group, or the like). The pyrazolomorphinan derivative can be used as an active ingredient in an analgesic, an antidepressant, an anxiolytic, or the like.
A method for therapeutic treatment of pain-associated anxiety or depression in a mammalian subject in need thereof, that includes administering to the subject an effective amount of a pharmaceutical composition containing a morphinan derivative that exhibits an opioid δ receptor agonist activity.
The present invention pertains to a medicament for preventing or treating nociceptive pain and/or visceral pain, the medicament comprising as an active ingredient a compound having a P2X4 receptor antagonistic action, or a pharmaceutically acceptable salt thereof.
A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
26.
PROPHYLACTIC OR THERAPEUTIC AGENT FOR RESPIRATORY DISEASES
The present invention pertains to a pharmaceutical composition for the prevention or treatment of respiratory diseases, particularly, inflammatory respiratory diseases, the pharmaceutical composition containing, as an active ingredient, a compound having a P2X4 receptor antagonizing effect or a pharmaceutically acceptable salt of said compound.
Provided are: an azepan derivative represented by general formula (I) and a pharmaceutically acceptable salt thereof (in the formula: R1 represents a hydrogen atom, a C1-6 alkyl group which may have a substituent, etc.; R2 and R3 are the same as or different from each other, and represent a hydrogen atom, a C1-6 alkyl group which may have a substituent, etc.; R4 and R5 are the same as or different from each other, and represent a hydrogen atom, a C1-6 alkyl group which may have a substituent, etc.; R6 represents a hydrogen atom, a C1-6 alkyl group which may have a substituent, etc.; R7 and R8 are the same as or different from each other, and represent a hydrogen atom, a C1-6 alkyl group which may have a substituent, etc.; R9 and R10 are the same as or different from each other, and represent a hydrogen atom, a C1-6 alkyl group which may have a substituent, etc.; R11 represents a hydrogen atom, a C1-6 alkyl group which may have a substituent, etc.; A and B differently represent a methyl group, a carbonyl group, etc.; and X represents a nitrogen atom or an N-oxide.).
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
28.
PROPHYLACTIC OR THERAPEUTIC AGENT FOR NEUROPATHIC PAIN ASSOCIATED WITH GUILLAIN-BARRE SYNDROME
A P2X4 receptor antagonist such as paroxetine, a diazepinedione derivative having the following formula (IX) is used as an agent for preventing or treating neuropathic pain associated with Guillain-Barré syndrome:
A P2X4 receptor antagonist such as paroxetine, a diazepinedione derivative having the following formula (IX) is used as an agent for preventing or treating neuropathic pain associated with Guillain-Barré syndrome:
A P2X4 receptor antagonist such as paroxetine, a diazepinedione derivative having the following formula (IX) is used as an agent for preventing or treating neuropathic pain associated with Guillain-Barré syndrome:
wherein R1 is hydrogen, a C1-8 alkyl group, or the like;
each R2 and R3 is hydrogen, a C1-8 alkyl group, or the like;
each of R4 and R5 is hydrogen or the like; and
W is a five-membered or six-membered heterocyclic ring optionally having one or more substituents and comprising one to four nitrogen atoms as the members of the ring.
A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
A61K 31/138 - Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
A61K 31/335 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
A61K 31/451 - Non-condensed piperidines, e.g. piperocaine having a carbocyclic ring directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
A61K 31/4525 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
C07D 403/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing aromatic rings
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
Diagnostic reagents for medical research; Diagnostic reagent kits consisting of chemical reagents, cell culture reagents, biochemical reagents for medical research Pharmaceutical preparations for Cardiovascular Disorders, Genitourinary Disorders, Gynecological diseases, Cancer and cancer supportive care, Eye Disorders, Neurologic Disorders, Psychiatric Disorders, Endocrine and Metabolic Disorders, Allergic Disorders, Gastrointestinal Disorders, Immune Diseases and Autoimmune Diseases, Respiratory Diseases, Musculoskeletal and Connective Tissue Disorders, Infectious Diseases, Dermatologic Disorders, Hematological Disorder, Inflammatory Diseases, Ear, Nose, Dental and Throat Disorders, Hepatic and Biliary Disorders, Kidney Diseases, Medicines for improving sleep, Medicines for controlling sickness from drinking, Medicines for controlling hangovers; Obstetric medicines being medical preparations for the treatment of endometriosis or adenomyosis; local, topical, general, inhalant anesthetic; Sedatives; Analgesic drugs; Alkalinizing agents being preparations for the lowering pH levels in patients; Anti-aging agents being pharmaceutical preparations for reducing the effects of aging in patients; reagent paper for medical purposes; pharmaceutical preparations for reducing pain, reducing inflammation; pharmaceutical preparations and substances with antipyretic properties anti-inflammatories and analgesic properties for the treatment of nociceptive pains, the treatment of neuropathic pains, the treatment of visceral pains, the treatment of rheumatoid arthritis, the treatment of low back pain, and the treatment of after surgery, trauma, and tooth extraction; pharmaceutical preparations for the treatment of gout and hyperuricemia; Pharmaceutical preparations for treating hypertension; pharmaceutical preparations and substances for the treatment of cancer; Hygiene agent, namely, medical cleanser for skin and wounds; Eye patches and skin patches for medical purposes, namely, pharmaceutical preparations for reducing pain, reducing inflammation; medicated ointments for treating dermatological conditions; Infusion drug for medical purposes, namely, pharmaceutical preparations for reducing pain, reducing inflammation that need to be administered gradually intravenously; Diagnostic agents and reagents for medical use; diagnostic reagents for medical purposes; Medical diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; In vitro diagnostic reagent for medical use; In vitro diagnostic reagents kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in determining allergies; medical oiled paper; Drug delivery agents in the form of wafers for wrapping powdered pharmaceuticals for medicine doses; gauze for dressings; empty capsules for pharmaceuticals; eyepatches for medical purposes; ear bandages; menstruation bandages; menstruation tampons; sanitary napkins; sanitary panties; absorbent cotton for medical purposes; adhesive plasters for medical purposes; bandages for dressings; liquid bandages spray; Breast-nursing pads; cotton swabs for medical use; lacteal flour for babies; dietary supplements for humans; dietetic beverages adapted for medical purposes; dietetic foods adapted for medical purposes; Vitamin fortified beverages for babies for medical purposes; food for babies; dietary-supplements-for-animals other than drugs; Semen for artificial insemination; ferments for pharmaceutical purposes; Food supplements, namely, antioxidant pills; dietary supplements for anti-aging immune system for humans; appetite suppressant pills; dietary fiber to aid digestion; pharmaceutical preparations for treating dry skin; Pharmaceutical preparations being medical application cream pharmaceuticals for treating skin conditions; pharmaceutical preparations for skin care; Nasal sprays for medical purposes Medical apparatus and instruments, namely, medical devices for use in diagnosing allergies; Medical diagnostic apparatus and instruments for diagnostic for immunotherapy medical purposes; Medical diagnostic apparatus and instruments, namely, medical devices for use in diagnosing allergies; apparatus for use in medical purpose for identifying allergens causing allergy, namely, medical devices for use in diagnosing allergies; medical diagnostic apparatus for testing and quantifying the amount of allergen-specific antibody; Genetic testing apparatus for medical purposes; medical measuring apparatus, namely, medical apparatus for measuring skin hydration; Medical diagnostic apparatus for measuring, testing and analyzing specimens reacted with diagnostic reagents; medical diagnostic apparatus, namely, immunoassay analyzer being medical diagnostic apparatus for testing for viruses; mobile medical apparatus for enzyme-linked immunosorbent assay, namely, medical diagnostic apparatus for testing for blood protein, DNA for allergy screening; medical diagnostic apparatus for testing and measuring specific immunoglobulin E (IgE) antibodies; Sanitary masks for personal use; dental materials being dental implants
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
Diagnostic reagents for medical research; Diagnostic reagent kits consisting of chemical reagents, cell culture reagents, biochemical reagents for medical research Pharmaceutical preparations for Cardiovascular Disorders, Genitourinary Disorders, Gynecological diseases, Cancer and cancer supportive care, Eye Disorders, Neurologic Disorders, Psychiatric Disorders, Endocrine and Metabolic Disorders, Allergic Disorders, Gastrointestinal Disorders, Immune Diseases and Autoimmune Diseases, Respiratory Diseases, Musculoskeletal and Connective Tissue Disorders, Infectious Diseases, Dermatologic Disorders, Hematological Disorder, Inflammatory Diseases, Ear, Nose, Dental and Throat Disorders, Hepatic and Biliary Disorders, Kidney Diseases, Medicines for improving sleep, Medicines for controlling sickness from drinking, Medicines for controlling hangovers; Obstetric medicines being medical preparations for the treatment of endometriosis or adenomyosis; local, topical, general, inhalant anesthetic; Sedatives; Analgesic drugs; Alkalinizing agents being preparations for the lowering pH levels in patients; Anti-aging agents being pharmaceutical preparations for reducing the effects of aging in patients; reagent paper for medical purposes; pharmaceutical preparations for reducing pain, reducing inflammation; pharmaceutical preparations and substances with antipyretic properties anti-inflammatories and analgesic properties for the treatment of nociceptive pains, the treatment of neuropathic pains, the treatment of visceral pains, the treatment of rheumatoid arthritis, the treatment of low back pain, and the treatment of after surgery, trauma, and tooth extraction; pharmaceutical preparations for the treatment of gout and hyperuricemia; Pharmaceutical preparations for treating hypertension; pharmaceutical preparations and substances for the treatment of cancer; Hygiene agent, namely, medical cleanser for skin and wounds; Eye patches and skin patches for medical purposes, namely, pharmaceutical preparations for reducing pain, reducing inflammation; medicated ointments for treating dermatological conditions; Infusion drug for medical purposes, namely, pharmaceutical preparations for reducing pain, reducing inflammation that need to be administered gradually intravenously; Diagnostic agents and reagents for medical use; diagnostic reagents for medical purposes; Medical diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; In vitro diagnostic reagent for medical use; In vitro diagnostic reagents kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in determining allergies; medical oiled paper; Drug delivery agents in the form of wafers for wrapping powdered pharmaceuticals for medicine doses; gauze for dressings; empty capsules for pharmaceuticals; eyepatches for medical purposes; ear bandages; menstruation bandages; menstruation tampons; sanitary napkins; sanitary panties; absorbent cotton for medical purposes; adhesive plasters for medical purposes; bandages for dressings; liquid bandages spray; Breast-nursing pads; cotton swabs for medical use; lacteal flour for babies; dietary supplements for humans; dietetic beverages adapted for medical purposes; dietetic foods adapted for medical purposes; Vitamin fortified beverages for babies for medical purposes; food for babies; dietary-supplements-for-animals other than drugs; Semen for artificial insemination; ferments for pharmaceutical purposes; Food supplements, namely, antioxidant pills; dietary supplements for anti-aging immune system for humans; appetite suppressant pills; dietary fiber to aid digestion; pharmaceutical preparations for treating dry skin; Pharmaceutical preparations being medical application cream pharmaceuticals for treating skin conditions; pharmaceutical preparations for skin care; Nasal sprays for medical purposes Medical apparatus and instruments, namely, medical devices for use in diagnosing allergies; Medical diagnostic apparatus and instruments for diagnostic for immunotherapy medical purposes; Medical diagnostic apparatus and instruments, namely, medical devices for use in diagnosing allergies; apparatus for use in medical purpose for identifying allergens causing allergy, namely, medical devices for use in diagnosing allergies; medical diagnostic apparatus for testing and quantifying the amount of allergen-specific antibody; Genetic testing apparatus for medical purposes; medical measuring apparatus, namely, medical apparatus for measuring skin hydration; Medical diagnostic apparatus for measuring, testing and analyzing specimens reacted with diagnostic reagents; medical diagnostic apparatus, namely, immunoassay analyzer being medical diagnostic apparatus for testing for viruses; mobile medical apparatus for enzyme-linked immunosorbent assay, namely, medical diagnostic apparatus for testing for blood protein, DNA for allergy screening; medical diagnostic apparatus for testing and measuring specific immunoglobulin E (IgE) antibodies; Sanitary masks for personal use; dental materials being dental implants
7 represent hydrogen atom and the like, X represents C, CH or N, Y represents N, NH or C(═O), provided that when X is N, Y is not N or NH, and when X is C or CH, Y is not C(═O), Z represents oxygen atom or sulfur atom, A represents benzene ring and the like, B represents NHC(═O) and the like, D represents an atomic bond and the like, E represents an atomic bond and the like, G represents benzene which may be substituted and the like, and m represents an integer of 0 to 5) or a pharmacologically acceptable salt thereof, and a P2X4 receptor antagonist.
A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
A61P 25/04 - Centrally acting analgesics, e.g. opioids
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C07D 243/10 - Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Provided is a composition for increasing muscle mass in a mammal, the composition comprising a citric acid, a salt of a citric acid, a hydrate thereof, or a mixture thereof.
To provide a novel T-type calcium channel blocker.
To provide a novel T-type calcium channel blocker.
A compound represented by the following General Formula (I), a tautomer or a stereoisomer of the compound, a pharmaceutically acceptable salt of the compound, or a solvate of the compound, the tautomer, the stereoisomer, or the salt is used as a T-type calcium channel blocker.
To provide a novel T-type calcium channel blocker.
A compound represented by the following General Formula (I), a tautomer or a stereoisomer of the compound, a pharmaceutically acceptable salt of the compound, or a solvate of the compound, the tautomer, the stereoisomer, or the salt is used as a T-type calcium channel blocker.
wherein A represents a phenyl which may have a substituent, a 4-membered to 6-membered heteroaryl ring composed of one to three identical or different heteroatoms selected from an oxygen atom, a sulfur atom, and a nitrogen atom and carbon atoms as ring-constituting atoms, or a heterocondensed ring composed of the heteroaryl ring and either a benzene ring or a 6-membered heteroaryl ring composed of one to two nitrogen atoms and carbon atoms, while here, the heteroaryl ring or the heterocondensed ring may have a substituent and is bonded to a nitrogen atom of the adjacent cyclic amino by means of a carbon atom constituting these rings;
B represents a phenyl which may have a substituent, a 5-membered or 6-membered heteroaryl ring composed of one to three identical or different heteroatoms selected from an oxygen atom, a sulfur atom, and a nitrogen atom and carbon atoms as ring-constituting atoms, or a heterocondensed ring composed of the heteroaryl ring and either a benzene ring or a 6-membered heteroaryl ring composed of one to two nitrogen atoms and carbon atoms, while here, the heteroaryl ring or the heterocondensed ring may have a substituent and is bonded to the adjacent cyclopropyl ring by means of a carbon atom constituting these rings;
R1 and R2, which may be identical or different, each represent a hydrogen atom, a halogen atom, or the like;
R3 represents a hydrogen atom, a halogen atom, or the like;
n and m, which may be identical or different, each represent 0 or 1; and p represents 1 or 2.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
A61P 25/04 - Centrally acting analgesics, e.g. opioids
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07F 7/08 - Compounds having one or more C—Si linkages
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 491/107 - Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 491/113 - Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
C07D 409/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
The present invention provides a pharmaceutical composition for treating or preventing gout or hyperuricemia, the pharmaceutical composition including a compound represented by General Formula (I):
The present invention provides a pharmaceutical composition for treating or preventing gout or hyperuricemia, the pharmaceutical composition including a compound represented by General Formula (I):
The present invention provides a pharmaceutical composition for treating or preventing gout or hyperuricemia, the pharmaceutical composition including a compound represented by General Formula (I):
wherein R1 represents an unsubstituted or substituted phenyl group, R2 represents a cyano group or a nitro group, R3 represents a hydrogen atom or a hydroxyl group, X represents an oxygen atom or —S(O)n—, n represents an integer of 0 to 2, and Y represents an oxygen atom or a sulfur atom, or a pharmaceutically acceptable salt thereof.
The present invention provides an enteric-coated preparation, including: a compound represented by General Formula (I)
The present invention provides an enteric-coated preparation, including: a compound represented by General Formula (I)
The present invention provides an enteric-coated preparation, including: a compound represented by General Formula (I)
wherein R1 is an unsubstituted phenyl group or a phenyl group substituted with a substituent, the substituent being at least one group selected from the group consisting of an alkyl group having 1 to 8 carbon atoms, an alkyl group having 1 to 8 carbon atoms substituted with a halogen atom, an alkoxy group having 1 to 8 carbon atoms, an alkoxycarbonyl group having 2 to 8 carbon atoms, a formyl group, a carboxyl group, a halogen atom, a phenyl group and a phenoxy group, R2 is a cyano group or a nitro group, R3 is a hydrogen atom or a hydroxyl group, X is an oxygen atom or —S(O)n—, n is an integer of 0 to 2, and Y is an oxygen atom or a sulfur atom, or a pharmaceutically acceptable salt thereof.
The present invention relates to the provision of a pharmaceutical composition that contains a compound represented by general formula (I), said compound being effective for the treatment, amelioration or prevention of κ-opioid receptor-related diseases and symptoms of various types (for example, pain, pruritus or substance addiction) with reduced or no sedation or drug aversion, a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof or a solvate thereof. Examples of the treatment, amelioration or prevention of the κ-opioid receptor-related diseases and symptoms of various types include the treatment, amelioration or prevention of pain, pruritus or substance addiction, in particular, the treatment, amelioration or prevention of drug addiction.
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K 31/706 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
Provided is a method for producing a composition, which contains a pharmaceutically acceptable salt of citric acid, a hydrate thereof, or a mixture thereof and has a moisture content of at most 4.0 mass%, the method comprising irradiating, with microwaves, a composition containing a pharmaceutically acceptable salt of citric acid, a hydrate thereof, or a mixture thereof.
Provided is a method for producing a phenol derivative represented by General Formula (B) and the like, including the step of: allowing metal lithium and liquid ammonia or a primary amine to act on a compound represented by General Formula (A) and the like:
Provided is a method for producing a phenol derivative represented by General Formula (B) and the like, including the step of: allowing metal lithium and liquid ammonia or a primary amine to act on a compound represented by General Formula (A) and the like:
wherein Rp1 represents a C6-10 aryl group optionally having a substituent, Rp2 represents a lower alkyl group and the like, and Rq1, Rq2, Rq3, and Rq4 represent a hydrogen atom or any substituent, or adjacent two of Rq1, Rq2, Rq3, and Rq4 optionally form a ring.
Provided is a reagent cartridge that can reduce the risk of infection caused by an operator touching a sample or the like during dispensation of the sample or handling of the reagent cartridge, can shorten the test time by improving the work efficiency, and can positively perform analysis of the sample. A reagent cartridge used for an analysis apparatus that analyzes a result based on the reaction of a sample and a reagent includes a sample containing part that contains the sample, a reagent containing part that contains the reagent, and an antibody containing part that contains the antibody, wherein the sample containing part, the reagent containing part, the antibody containing part, and the sample containing part are arranged on the same surface, and the sample containing part includes an injection part and a liquid suction part.
The present invention provides a pharmaceutical composition for the treatment or prevention of stress-related disorders, stress-induced anxiety disorders, or stress-related disorders or anxiety disorders associated with depression that includes a selective δ-opioid receptor agonist as an active ingredient, the selective δ-opioid receptor agonist preferably also having a μ-opioid receptor antagonist action and a κ-opioid receptor antagonist action.
A61P 43/00 - Drugs for specific purposes, not provided for in groups
A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/4725 - Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
Provided is, for example, a method for producing a morphinan derivative represented by General Formula (II), including the step of: allowing metal sodium and ethylenediamine to act on a morphinan derivative represented by General Formula (I) in presence of an auxiliary solvent.
2.
A medicament for treating or preventing pruritus is provided. For the medicament for treating or preventing pruritus, a compound having a blocking action on Cav3.2T-type calcium channels represented by General Formulas (I) to (VI), a tautomer of the compound, a stereoisomer of the compound, a pharmaceutically acceptable salt thereof, or a solvate thereof is used as an active ingredient.
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/541 - Non-condensed thiazines containing further heterocyclic rings
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
A61K 31/4427 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems
A61K 31/438 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring being spiro-condensed with carbocyclic or heterocyclic ring systems
The present invention relates to a pharmaceutical composition for treating or preventing acidosis in chronic kidney disease with anemia, the pharmaceutical composition containing citric acid, a pharmaceutically acceptable salt of citric acid, a hydrate thereof, or a mixture thereof, in which the pharmaceutical composition is in a form of a tablet.
SCHOOL JURIDICAL PERSON HIGASHI-NIPPON-GAKUEN (Japan)
THE UNIVERSITY OF TOKYO (Japan)
NIPPON CHEMIPHAR CO., LTD. (Japan)
Inventor
Hiraoka Miki
Okamoto Ken
Hirano Masuharu
Abstract
The present invention provides a pharmaceutical composition that is for intracellular ATP enhancement, and that contains a compound represented by general formula (I) (in the formula, R1represents an unsubstituted or substituted phenyl group, R2represents a cyano group or a nitro group, R3nn-, n represents an integer of 0-2, and Y represents an oxygen atom or a sulfur atom), or a pharmaceutically acceptable salt thereof.
Provided is a method which is for preparing a morphinan derivative having a diaryl ether skeleton represented by general formula (III) (In the formula, R1represents a hydrogen atom, etc., R2, R3, and R4represent the same or different hydrogen atom, or an arbitrary substituent, etc., R5represent a hydrogen atom, a hydroxy group, etc., R14and R15 represent the same or different hydrogen atom, or arbitrary substituent, etc.), and in which a phenyl group is introduced into the 4-position phenol of a morphinan derivative through the Ullmann reaction of a system using a monovalent copper compound or a novel catalytic system simultaneously using a monovalent copper compound and zero-valent metallic copper.
The present invention pertains to a pharmaceutical composition that is for preventing, suppressing, or treating symptoms associated with an allergic reaction and that includes a compound having a P2X4 receptor antagonist effect or a pharmacologically acceptable salt of the compound as an active ingredient.
This method for producing a morphinan derivative by means of a reduction reaction using formic acid or the like is represented by the following general formula (II).
C07D 489/02 - Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine
A61P 25/04 - Centrally acting analgesics, e.g. opioids
There is provided a pharmaceutical composition which includes, as an active ingredient, a combination drug formulation of potassium citrate and sodium citrate hydrate or a sodium bicarbonate formulation. The prevention or treatment of nocturnal polyuria is achieved by administering the pharmaceutical composition.
The present invention relates to a pharmaceutical composition for renal protection in chronic kidney disease, which contains a citric acid, a pharmaceutically acceptable salt of a citric acid, or a hydrate thereof; and a mixture of the citric acid, the pharmaceutically acceptable salt of the citric acid, and the hydrate thereof, and is a tablet.
KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION (Japan)
NIPPON CHEMIPHAR CO., LTD. (Japan)
Inventor
Fukui, Michiaki
Hashimoto, Yoshitaka
Nakai, Toshiki
Ueyama, Shigeki
Yamauchi, Noboru
Abstract
The present invention provides a composition including citric acid, a pharmaceutically acceptable salt of citric acid, a hydrate of citric acid, a hydrate of the pharmaceutically acceptable salt of citric acid, or a mixture thereof. Administration or ingestion of the previous period composition inhibits renal fibrosis in diabetic nephropathy.
The present invention provides a food composition or pharmaceutical composition which includes, as an active ingredient, at least one substance selected from the group consisting of citric acid and a salt thereof, or sodium bicarbonate. Ingestion or administration of the food composition or pharmaceutical composition leads to an improvement in quality of sleep.
Provided is a biochemical reaction substrate which can achieve higher test sensitivity and shorter testing time in an allergy test, which can also reduce a required amount of blood or the like needed as a specimen and decrease the number of test steps, thereby facilitating performance of the test, and which is to be used in an allergy test in which infection risk of the test staff is reduced. A biochemical reaction substrate, including: a reaction plate; an absorber; a reaction plate storing portion for storing the reaction plate; an absorber storing portion for storing the absorber; a storage container having a heated portion; and a cover assembled to the storage container so as to cover at least a part of the reaction plate and the absorber stored in the storage container, wherein the reaction plate includes a reaction area in which a specific binding substance that specifically reacts with a substance to be tested in a specimen is immobilized, and a flow passage that connects the absorber and the reaction area, and wherein the cover includes an injection hole for injecting a specimen or the like into the reaction plate.
G01N 35/00 - Automatic analysis not limited to methods or materials provided for in any single one of groups Handling materials therefor
G01N 35/02 - Automatic analysis not limited to methods or materials provided for in any single one of groups Handling materials therefor using a plurality of sample containers moved by a conveyor system past one or more treatment or analysis stations
55.
AGENT FOR SUPPRESSING ALCOHOL SICKNESS OR HANGOVER DUE TO ALCOHOLIC BEVERAGE INGESTION
The present invention provides a food composition or pharmaceutical composition which includes, as an active ingredient, citric acid or a salt thereof. Ingestion or administration of the food composition or pharmaceutical composition leads to suppression of alcohol sickness or hangover due to alcoholic beverage ingestion; suppression of an increase in blood alcohol level, an increase in blood acetaldehyde level, or an increase in blood acetic acid level due to alcoholic beverage ingestion; suppression of a decrease in blood pyruvic acid level due to alcoholic beverage ingestion; suppression of an abnormal blood lactic acid/pyruvic acid ratio due to alcoholic beverage ingestion; suppression of an increase in blood alcohol level immediately after alcohol ingestion; suppression of alcohol absorption; promotion of alcohol metabolism; or an increase in blood ornithine level, blood serotonin level, blood taurine level, blood cystine level, or blood nicotine amide level.
A compound represented by General Formula (I), a tautomer, a stereoisomer, or a pharmaceutically acceptable salt of the compound, or a solvate thereof is used as a voltage-dependent T-type calcium channel inhibitor,
n represents 0 or 1.
C07D 235/16 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 403/08 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing alicyclic rings
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Provided is a pharmaceutical composition useful for improving the quality of sleep, relieving stress, and reducing feelings of fatigue in a mammalian (e.g., human) subject through ingestion or administration of a composition containing at least one substance selected from the group consisting of citric acid and salts thereof.
Provided is a pharmaceutical composition containing a citric acid, a pharmaceutically acceptable salt of a citric acid, a hydrate thereof, or a mixture thereof. The administration of this pharmaceutical composition enables a renal function to be protected or a dietary acid load on the kidneys to be alleviated.
The present invention relates to a medicine for preventing or treating pain in nociceptive pain, inflammatory pain, or neuropathic pain, the medicine comprising, as an active ingredient, a compound having a P2X4 receptor antagonist action, a tautomer of the compound, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof. The medicine has no effect on driving or machine operation ability, has no effect on car driving ability, does not require any restriction to administration thereof to a patient engaging in operation of a dangerous machine including driving a car, or can be administered to a patient engaging in operation of a dangerous machine including driving a car.
Provided is a metabolism improving agent that contains, for example, an alkalizing agent such as an acidosis improving agent or a urinary alkalizing agent as an active ingredient, and has actions such as improvement of insulin resistance, improvement of pituitary and adrenal functions, and reduction of visceral fat accumulation.
The present invention addresses the problem of providing a method for producing a high-purity N-dealkylated cyclic secondary amine via a simple and non-turbulent method. An N-dealkylated cyclic secondary amine can be obtained by reacting a cyclic tertiary amine, in which a substituent expressed by R122- (wherein R1is a hydrogen atom, an optionally substituted alkyl, a vinyl, a cyclopropyl, or an optionally substituted phenyl) is bonded to the nitrogen atom, and a dialkyl azodicarboxylate, and reacting a compound represented by EWG122-EWG2(wherein EWG1and EWG2 represent identical or different electron-accepting groups) with the reaction product thereof.
C07D 451/02 - Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.02,4] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamineCyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.02,4] nonane ring systems, e.g. tropaneCyclic acetals thereof
C07D 451/10 - Oxygen atoms acylated by aliphatic or araliphatic carboxylic acids, e.g. atropine, scopolamine
C07D 451/12 - Oxygen atoms acylated by aromatic or heteroaromatic carboxylic acids, e.g. cocaine
C07D 489/12 - Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14 the bridge containing only two carbon atoms
[Problem] To provide an epoxy azepan derivative having an agonist activity against κ-opioid receptor. [Solution] An azepan derivative represented by general formula (I) or a pharmaceutically acceptable salt thereof is used as an analgetic drug and the like. (In the formula, R11-61-6 alkyl group, or the like; R2and R3are hydrogen or the like; R4and R5are hydrogen or the like; R61-61-6 alkoxy group, or the like; R7and R8are hydrogen or the like; R9and R10are hydrogen or the like; R111-61-6 alkyl group, or the like; X is N or the like; A and B, which are different, are NH, a carbonyl group, or general formula (II).) (In the formula, (R12and R131-61-6 alkyl group or the like; R14 is heteroaryl, a cyclic amino group, or the like; Y is a methylene group, a carbonyl group, or the like; Z is NH, O, or the like; m is an integer from 0 to 1; n is an integer from 0 to 3 (if Z is a bond, m and n are not simultaneously 0); and * is a bond.)
A61P 25/04 - Centrally acting analgesics, e.g. opioids
C07D 491/147 - Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine
The present invention provides a compound having a selective opioid δ receptor agonist effect. The present invention provides a pyrazolomorphinan derivative represented by general formula (1) (in the formula, (II) R1represents a hydrogen atom, an alkyl group, a cycloalkylmethyl group, or the like, R2represents a hydrogen atom or a hydroxy protecting group, R3represents a hydroxy group, an alkyl group, a partially unsaturated heterocyclic group, an aryl group, a heteroaryl group, or the like; and R4 represents a hydrogen atom, an alkyl group, an aralkyl group, a cycloalkyl group, a cycloalkyl alkyl group, a saturated heterocyclic group, an aryl group, a heteroaryl group, or the like). The pyrazolomorphinan derivative can be used as an active ingredient in an analgesic, an antidepressant, an anxiolytic, or the like.
A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japan)
Inventor
Imai, Toshiyasu
Kawasaki, Toru
Ogawa, Toru
Inoue, Kazuhide
Abstract
A medicament for preventive and/or therapeutic treatment of multiple sclerosis, especially a pain accompanying multiple sclerosis such as neuropathic pain, which contains a compound having a P2X4 receptor antagonist activity such as a compound represented by the general formula (IH), or a salt thereof or a hydrate or solvate thereof as an active ingredient.
The present invention relates to a food composition comprising an alkalinizing agent, particularly an alkali metal salt of citric acid. Ingestion of the food composition maintains kidney function.
Provided are: an azepan derivative represented by general formula (I) and a pharmaceutically acceptable salt thereof (in the formula: R11-61-6 alkyl group which may have a substituent, etc.; R2and R31-61-6 alkyl group which may have a substituent, etc.; R4and R51-61-6 alkyl group which may have a substituent, etc.; R61-61-6 alkyl group which may have a substituent, etc.; R7and R81-61-6 alkyl group which may have a substituent, etc.; R9and R101-61-6 alkyl group which may have a substituent, etc.; R111-61-6 alkyl group which may have a substituent, etc.; A and B differently represent a methyl group, a carbonyl group, etc.; and X represents a nitrogen atom or an N-oxide.).
C07F 7/10 - Compounds having one or more C—Si linkages containing nitrogen
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japan)
Inventor
Sakuma Shogo
Imai Toshiyasu
Inoue Kazuhide
Abstract
[Problem] To provide a novel diazepine derivative having a P2X4 receptor antagonizing action. [Solution] The present invention pertains to: a compound represented by general formula (I) (in the formula, R1and R2may be the same or different, and represent a hydrogen atom, a C1-8 alkyl group, a C2-8 alkenyl group, a C1-8 alkoxy group, a C1-8 alkyl group substituted by 1 to 3 halogen atoms, a C1-8 alkoxy group substituted by 1 to 3 halogen atoms, a halogen atom, a hydroxyl group, a nitro group, a cyano group, an amino group, a C1-8 alkylamino group, a C2-8 dialkylamino group, a C2-8 acylamino group, a C2-8 acylamino group substituted by 1 to 3 halogen atoms, a C1-8 alkylsulfonylamino group, a carboxyl group, a C2-8 acyl group, an alkoxycarbonyl group (where the number of carbon atoms in the alkoxy moiety is 1-8), a carbamoyl group, a C1-8 alkylthio group, a C1-8 alkylsulfinyl group, a C1-8 alkylsulfonyl group, or a sulfamoyl group; and R3 represents an optionally substituted 5- or 6-membered ring heterocycle including 1 to 4 nitrogen atoms as a ring constituent element); a tautomer, stereoisomer, or pharmacologically acceptable salt of the compound; or a hydrate or solvate thereof.
A61P 25/04 - Centrally acting analgesics, e.g. opioids
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C07D 403/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 413/10 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
A morphinan derivative represented by the following general formula (I):
2; and Y represents C(═O)); a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof is used as an anxiolytic drug, antidepressant, etc.
Provided is a reagent cartridge with which it is possible to: reduce the risk of a worker acquiring infection through contact with a sample or the like while dispensing samples or handling a reagent cartridge; shorten examination time due to improved work efficiency; and ensure analysis of a sample. This reagent cartridge is to be used in an analyzing device for analyzing a result based on a reaction between a sample and a reagent, and is provided with: a sample housing part for housing the sample; a reagent housing part for housing the reagent; and an antibody housing part for housing an antibody, wherein the sample housing part, the reagent housing part, and the antibody housing part are all arranged on the same plane, and the sample housing part is equipped with an injection section and a liquid absorption section.
G01N 35/02 - Automatic analysis not limited to methods or materials provided for in any single one of groups Handling materials therefor using a plurality of sample containers moved by a conveyor system past one or more treatment or analysis stations
Provided is a method for producing a morphinan derivative represented by general formula (II), etc., by causing metallic sodium and ethylenediamine to act on a morphinan derivative represented by general formula (I) in the presence of an auxiliary solvent. (In the formula, R11-103-62-66-106-10 aryl group or heteroaryl group, R2represents an amino protecting group, R3represents a methoxy group, R4and R5represent a hydrogen atom or a hydroxy group, R6and R7represent a hydrogen atom or an electron-donating group; here, R6and R722.)
The present invention provides: a method for producing a phenol derivative represented by general formula (B), or the like, by having lithium metal and liquid ammonia or a primary amine act on a compound represented by general formula (A), or the like; and the like. (In the formulae, Rp16-106-10 aryl group; Rp2represents a lower alkyl group or the like; and each of Rq1, Rq2, Rq3and Rq4represents a hydrogen atom or an arbitrary substituent, or alternatively, adjacent two moieties among Rq1, Rq2, Rq3and Rq4 may combine with each other to form a ring.)
The present invention pertains to a medicament for preventing or treating cough, including, as an active ingredient, a compound having P2X4 receptor antagonistic action, a tautomer, stereoisomer, or pharmaceutically acceptable salt of the compound, or a hydrate or solvate thereof.
A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C07D 243/10 - Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
The present invention provides a pharmaceutical composition for treating or preventing gout or hyperuricemia that contains a compound represented by general formula (I) (in the formula, R1represents a substituted or unsubstituted phenyl group, R2represents a cyano group or a nitro group, R3nn-, n represents an integer of 0-2, and Y represents an oxygen atom or a sulfur atom) or a pharmaceutically acceptable salt thereof.
The present invention provides an enteric-coated preparation that comprises a compound represented by general formula (1) [wherein: R1represents an unsubstituted phenyl group or a phenyl group substituted with a substituent, said substituent being at least one group selected from the group consisting of an alkyl group having 1-8 carbon atoms, a halogenated alkyl group having 1-8 carbon atoms, an alkoxy group having 1-8 carbon atoms, an alkoxycarbonyl group having 2-8 carbon atoms, a formyl group, a carboxyl group, a halogen atom, a phenyl group and a phenoxy group; R2represents a cyano group or a nitro group; R3nn-; n represents an integer of 0–2; and Y represents an oxygen atom or a sulfur atom] or a pharmaceutically acceptable salt thereof.
The present invention relates to a pharmaceutical composition that is used for treating or preventing acidosis of chronic kidney disease with anemia and contains citric acid, a pharmaceutically acceptable salt of citric acid, a hydrate thereof, or a mixture thereof, wherein the pharmaceutical composition is in the form of a tablet.
Provided is a medicinal drug for treating or preventing pruritus. As a medicinal drug for treating or preventing pruritus, the present invention uses, as an active ingredient, a compound that has an effect of blocking the Cav3.2 T-type calcium channel and that is represented by any one of general formulae (I)-(VI), a tautomer, a stereoisomer, or a pharmaceutically acceptable salt of the compound, or a solvate thereof.
A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C07D 207/14 - Nitrogen atoms not forming part of a nitro radical
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 409/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 205/04 - Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
A61K 31/397 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
A61K 31/422 - Oxazoles not condensed and containing further heterocyclic rings
A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
A61K 31/4355 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/5386 - 1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
A61K 31/541 - Non-condensed thiazines containing further heterocyclic rings
Provided is a medicinal drug for treating or preventing rheumatoid arthritis. As a medicinal drug for treating or preventing rheumatoid arthritis, the present invention uses, as an active ingredient, a compound that has an effect of blocking the T-type calcium channel (Cav3.2 channel) and that is represented by any one of general formulae (I)-(VI), a tautomer, a stereoisomer, or a pharmaceutically acceptable salt of the compound, or a solvate thereof.
A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C07D 207/14 - Nitrogen atoms not forming part of a nitro radical
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 409/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 205/04 - Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
A61K 31/397 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
A61K 31/422 - Oxazoles not condensed and containing further heterocyclic rings
A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
A61K 31/4355 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/5386 - 1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
A61K 31/541 - Non-condensed thiazines containing further heterocyclic rings
The present invention relates to a solid dispersion containing a compound represented by General Formula (I):
n—; n is an integer of 0 to 2; Y is an oxygen atom or a sulfur atom, or a pharmaceutically acceptable salt thereof and a hypromellose derivative.
8 may be the same as or different from each other and represent a hydrogen atom, a halogen atom, an alkyl group having 1 to 8 carbon atoms, an alkoxy group having 1 to 8 carbon atoms, an alkyl group having 1 to 8 carbon atoms substituted with 1 to 3 halogen atoms, an alkoxy group having 1 to 8 carbon atoms substituted with 1 to 3 halogen atoms, a hydroxy group, an amino group, a carboxyl group, a mercapto group, an alkylsulfanyl group having 1 to 8 carbon atoms, a nitro group, or a cyano group).
7 represent hydrogen atom and the like, X represents C, CH or N, Y represents N, NH or C(═O), provided that when X is N, Y is not N or NH, and when X is C or CH, Y is not C(═O), Z represents oxygen atom or sulfur atom, A represents benzene ring and the like, B represents NHC(═O) and the like, D represents an atomic bond and the like, E represents an atomic bond and the like, G represents benzene which may be substituted and the like, and m represents an integer of 0 to 5) or a pharmacologically acceptable salt thereof, and a P2X4 receptor antagonist.
A61P 25/04 - Centrally acting analgesics, e.g. opioids
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C07D 243/10 - Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
The present invention relates to a morphinan derivative that has an opioid κ receptor agonist effect and that is represented by general formula (I). (In the formula, R11-61-6 alkyl group that may have a substituent, or the like; R2and R31-61-6 alkyl group that may have a substituent, or the like; R4and R51-61-6 alkyl group that may have a substituent, or the like; R61-61-6 alkoxy group that may have a substituent, or the like; R71-61-6 alkyl group that may have a substituent, or the like; R8and R91-61-6 alkyl group that may have a substituent, or the like; R10and R111-61-6 alkyl group that may have a substituent, or the like; R12and R13are the same or different and each indicate a hydrogen atom or the like; R14 indicates a heteroaryl group that may have a substituent or the like; X indicates a nitrogen atom or the like; Y indicates C=O or the like; Z indicates an oxygen atom or the like; a double line consisting of a solid line and a broken line indicates a single bond or the like; m indicates an integer of 0-1; and n indicates an integer of 0-3.) The present invention also relates to a tautomer, a stereoisomer, or a pharmaceutically acceptable salt of said compound, or a solvate of said substances.
C07D 489/00 - Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine
The present invention provides a food composition or pharmaceutical composition that includes, as an active ingredient: at least one substance selected from the group that consists of citric acid and salts thereof; or sodium bicarbonate. Intake or administration of the food composition or pharmaceutical composition has been found to improve the quality of sleep.
Provided are a pharmaceutical composition, which comprises, as an active ingredient, a potassium citrate and sodium citrate hydrate preparation or a sodium hydrogencarbonate preparation, etc. By administering the pharmaceutical composition according to the present invention, etc., the prevention or treatment of nocturia can be achieved.
The present invention provides a food composition or pharmaceutical composition that includes citric acid or a salt thereof as an active ingredient. Intake or administration of the food composition or pharmaceutical composition has been found: to suppress alcohol sickness or hangover caused by alcoholic beverage intake; to suppress increases in blood alcohol concentration, blood acetaldehyde concentration, or blood acetic acid concentration caused by alcoholic beverage intake; to suppress decreases in blood pyruvic acid concentration caused by alcoholic beverage intake; to suppress abnormalities in blood lactic acid/pyruvic acid ratios caused by alcoholic beverage intake; to suppress increases in blood alcohol concentration immediately after alcohol intake; to suppress alcohol absorption; to promote alcohol metabolism; or to increase blood ornithine concentration, blood serotonin concentration, blood taurine concentration, blood cystine concentration, or blood nicotinamide concentration.
KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION (Japan)
NIPPON CHEMIPHAR CO., LTD. (Japan)
Inventor
Fukui Michiaki
Hashimoto Yoshitaka
Nakai Toshiki
Ueyama Shigeki
Yamauchi Noboru
Abstract
Provided is a composition that comprises citric acid, a pharmaceutically acceptable citric acid salt, a hydrate thereof or a mixture of the same. By administering or taking this composition, renal fibrosis in diabetic nephropathy is inhibited.
The present invention pertains to a pharmaceutical composition as a tablet for renal protection in chronic kidney disease, the composition containing a citric acid, a pharmaceutically acceptable salt of the citric acid, or a hydrate or mixture thereof.
A morphinan derivative represented by the following general formula (I):
2; and Y represents C(═O)); a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof is used as an anxiolytic drug, antidepressant, etc.
A medicine for preventing or treating pain such as nociceptive pain, inflammatory pain or neuropathic pain, said medicine comprising as an active ingredient a compound having P2X4 receptor antagonism, a tautomer or stereoisomer of the compound, a pharmaceutically acceptable salt thereof or a hydrate or solvate of the same. This medicine neither affects the ability to drive or operate machines, nor affects the ability to drive motor vehicles, nor requires any restriction to administration thereof to patients operating dangerous machines including driving motor vehicles, but can be administered to patients operating dangerous machines including driving motor vehicles.
A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
A61P 25/04 - Centrally acting analgesics, e.g. opioids
A61P 43/00 - Drugs for specific purposes, not provided for in groups
The purpose of the present invention is to provide a novel T-type calcium channel blocker. A compound represented by general formula (I), a tautomer or stereoisomer of the compound, a pharmaceutically acceptable salt thereof or a solvate of the same is used as a T-type calcium channel blocker. (In the formula: A represents optionally substituted phenyl, a 4-6 membered heteroaryl ring consisting of, as ring-constituting atoms, 1-3 heteroatoms, said heteroatoms being the same or different and selected from an oxygen atom, a sulfur atom and a nitrogen atom, and carbon atom(s), or a hetero fused ring consisting of the heteroaryl ring and a benzene ring or a 6-membered heteroaryl ring consisting of 1-2 nitrogen atoms and carbon atoms (wherein the heteroaryl ring and the hetero fused ring are optionally substituted) and is bonded to the nitrogen atom of the adjacent cyclic amine through a carbon atom constituting the ring; B represents optionally substituted phenyl, a 5- or 6-membered heteroaryl ring consisting of, as ring-constituting atoms, 1-3 heteroatoms, said heteroatoms being the same or different and selected from an oxygen atom, a sulfur atom and a nitrogen atom, and carbon atoms, or a hetero fused ring consisting of the heteroaryl ring and a benzene ring or a 6-membered heteroaryl ring consisting of 1-2 nitrogen atoms and carbon atoms (wherein the heteroaryl ring and the hetero fused ring are optionally substituted) and is bonded to the adjacent cyclopropyl ring through a carbon atom constituting the ring; R1and R2may be either the same or different and represent a hydrogen atom, a halogen atom, etc.; R3 represents a hydrogen atom, a halogen atom, etc.; n and m may be either the same or different and represent 0 or 1; and p represents 1 or 2.)
C07D 205/04 - Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
A61K 31/397 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
A61K 31/422 - Oxazoles not condensed and containing further heterocyclic rings
A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
A61K 31/428 - Thiazoles condensed with carbocyclic rings
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/4427 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/5386 - 1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
A61K 31/541 - Non-condensed thiazines containing further heterocyclic rings
A61P 25/04 - Centrally acting analgesics, e.g. opioids
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C07D 207/14 - Nitrogen atoms not forming part of a nitro radical
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 409/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
Provided is a metabolism improving agent that comprises an alkalizer such as an acidosis ameliorating agent or a urine alkalizer as an active ingredient and has effects of improving insulin resistance, improving pituitary and adrenal functions, reducing visceral fat accumulation, etc.
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A61P 5/00 - Drugs for disorders of the endocrine system
A61P 5/04 - Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
A61P 5/12 - Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
A61P 5/46 - Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
The present invention relates to a pharmaceutical composition comprising a morphinan derivative that exhibits an opioid δ receptor agonist activity. By administering the pharmaceutical composition provided by the present invention, opioid δ receptor-related diseases (for example, headache) can be treated or prevented.
Provided are: a compound having a xanthine oxidase inhibitory activity, represented by general formula (I) (in the formula: R1181818288 alkoxycarbonyl group, a formyl group, a carboxyl group, and a halogen atom; R2is a cyano group or a nitro group; R3and R418nn-; n is an integer of 0 to 2; and Y is an oxygen atom or a sulfur atom); a tautomer or a stereoisomer of said compound, or a pharmaceutically acceptable salt thereof; and a solvate thereof.
A method for producing compounds represented by the following general formula through a dealkylation reaction in which a boron trifluoride complex is used (in the formula, R11-101-10 alkyl group, etc., R21-101-10 alkyl group, etc., R3is a hydrogen atom, etc., R4is a hydrogen atom, etc., R5and R6are the same or different and are hydrogen atoms, etc., R7and R8are the same or different and are hydrogen atoms, etc., R9, R10, R111-101-10 alkyl groups, etc., and R12is a -C(=O)OR13group, a -C(=O)-R14group, a -C(O=)NR20R21 group, etc.).
C07D 489/12 - Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14 the bridge containing only two carbon atoms
The present invention pertains to a drug for preventing or treating cough, the drug containing as an active ingredient a compound having a P2X4 receptor antagonizing action, a tautomer, stereoisomer, or pharmacologically acceptable salt of said compound, or a hydrate or solvate thereof.
A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
A61K 31/498 - Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
Provided is a method for producing morphinan derivatives having the buprenorphine skeleton. In the method, compounds represented by formula (III) are obtained using a Diels-Alder condensation reaction between (I) and (II). By introducing an electron-withdrawing protective group (X) onto an amide moiety, the amount of dienophile (II) for the condensation reaction is reduced, polymer impurities from (II) are decreased, and the overall reaction time is reduced, thus improving upon the conventional method. This novel method can be applied to industrial-scale production without isolation of the produced intermediates between the steps from the production of (II) from (V) and R922 to the production of (IV) from (III) by the deprotection of (X).
C07D 489/12 - Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14 the bridge containing only two carbon atoms
C07C 271/64 - Y being a hydrogen or a carbon atom, e.g. benzoylcarbamates
96.
BIOCHEMICAL REACTION SUBSTRATE AND ANALYSIS DEVICE
Provided is a biochemical reaction substrate that makes it possible to achieve high-sensitivity allergy testing in a shorter amount of time, reduces the amount of blood or the like needed as a sample for allergy testing, makes allergy testing easy by reducing the number of testing steps, and can be used for allergy testing that reduces the risk of a tester being infected. A biochemical reaction substrate that comprises: a housing container that comprises a reaction plate, an absorption body, a reaction plate housing part that is for housing the reaction plate, an absorption body housing part that is for housing the absorption body, and a temperature-controlled part; and a cover that is installed on the housing container so as to cover at least a portion of the reaction plate and the absorption body that are housed in the housing container. The reaction plate has: a reaction area to which is fixed a specific binding substance that reacts specifically with a test substance in a sample; and a flow passage part that connects the absorption body and the reaction area. The cover comprises an injection hole that is for injecting a sample or the like onto the reaction plate.
The present invention relates to methods for producing 5-(2-fluorophenyl)-1H-pyrrole-3-carboxyaldehyde by formylation and deprotection and producing 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate by sulfonylation, etc.
C07D 207/333 - Radicals substituted by oxygen or sulfur atoms
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
C07D 207/32 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07B 51/00 - Introduction of protecting groups or activating groups, not provided for in groups
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations; Preparations for destroying vermin; Fungicides; Herbicides; Absorbent cotton; Adhesive plasters; Adhesive tapes for medical purposes; Pharmaceutical agents affecting respiratory organs; Antiparasitics; Cellular function activating agents for medical purposes; Pharmaceutical preparations for treating chemical imbalances; Drug delivery agents; Pharmaceutical agents for uro-genital and anal organs; Ameliorating or therapeutic drug for dyslipidemia; Amino acid preparations for medical purposes; Amino acid preparations for veterinary use; Analgesics; Antiallergic medicines; Antibiotics; Anti-cancer preparations; Antidiabetic pharmaceuticals; Antihyperglycemic pharmaceutical agents; Antihypertensives; Anti-inflammatory preparations; Antimicrobials for dermatologic use; Antioxidant pills; Antiphlogistic pills; Anti-platelet aggregation agent; Antisarcoma preparations; Appetite suppressant pills; Bandages for dressings; Beverages for infants; Biological preparations for medical purposes; Breast-nursing pads; Cardiovascular preparations; Chemotherapeutics; Collodion for pharmaceutical purposes; Cotton swabs for medical use; Creamy medicated milk with medical properties; Crude drugs, charred drugs and dried plants for moxibustion therapy; Dental composite materials; Materials for dental fillings; Diagnostic preparations for medical use; Diagnostic preparations for veterinary use; Medical diagnostic reagents; Veterinary diagnostic reagents; Diagnostic reagents for laboratory use for medical or veterinary purposes; Diagnostic reagents for medical purposes; Diagnostic reagents kits for medical purposes; Dietary fiber; Dietary supplements for animals; Dietary supplements for humans; Dietetic beverages adapted for medical purposes; Dietetic food adapted for medical purposes; Dietetic substances adapted for medical use; Drug delivery agents in the form of edible wafers for wrapping powdered pharmaceuticals; Ear bandages; Empty capsules for pharmaceuticals; Enzymes for medical purposes; Eyepatches for medical purposes; Febrifuges; Food for babies; Gauze for dressings; Hemotoropic agents; Hormones for medical purposes; In vitro diagnostic reagents for medical purposes; Intravenous fluids used for rehydration, nutrition and the delivery of pharmaceutical preparations; Lacteal flour for babies; Antiseptic liquid bandages; Medicinal preparations for ingestion through the mouth in the form of drops, capsules, tablets or compressed tablets; Menstruation bandages; Menstruation tampons; Mosquito-repellent incenses; Narcotics; Nutritional additives to foodstuffs for humans or animals, and substitutes therefor, for medical purposes; Medicine tonics and substitutes therefor; Nutritional supplements; Oiled paper for medical purposes; Ointments for pharmaceutical purposes; Adhesive patches for medical purposes; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical agents affecting digestive organs; Pharmaceutical agents affecting metabolism; Pharmaceutical agents affecting peripheral nervous system; Pharmaceutical agents affecting sensory organs; Pharmaceutical agents against dry skin; Pharmaceutical agents for epidermis; Pharmaceutical preparations for infusion; Pharmaceutical preparations for the treatment of gout; Drug delivery agents in the form of wafers for wrapping powdered pharmaceuticals; Pharmaceutical agents for treating physically caused lesions; Pre-filled syringes for medical purposes; Preparations of microorganisms for medical or veterinary use; Radio-isotope markers for therapeutic or diagnostic use; Reagent paper for medical purposes; Reagents kits for in vitro diagnostics for medical purposes; Sanitary napkins; Sanitary panties; Sanitary preparations for medical purposes; Semen for artificial insemination; Synthetic biocides; Therapeutic agent for dysuria; Therapeutic agents for hyperuricemia; Transplants [living tissues]; Tumor suppressing agents; Veterinary preparations; Vitamin preparations.
SHIZUOKA PREFECTURAL UNIVERSITY CORPORATION (Japan)
NIPPON CHEMIPHAR CO., LTD. (Japan)
Inventor
Itai Shigeru
Noguchi Shuji
Iwao Yasunori
Hirano Masuharu
Ohta Takashi
Yamakawa Tomio
Abstract
The present invention pertains to a solid dispersion containing a compound represented by general formula (I) (wherein R1represents an unsubstituted phenyl group or a phenyl group substituted with a substituent; the substituent represents an alkyl group comprising 1–8 carbon atoms, an alkyl group comprising 1–8 carbon atoms substituted with a halogen atom, an alkoxy group comprising 1–8 carbon atoms, an alkoxy carbonyl group comprising 2–8 carbon atoms, a formyl group, a carboxyl group, a halogen atom, a phenyl group, or a phenoxy group; R2represents a cyano group or a nitro group; R3nn-; n represents an integer in a range of 0–2; and Y represents an oxygen atom or a sulfur atom), or a pharmaceutically acceptable salt thereof, and a hypromellose derivative.
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
Pharmaceuticals, medical and veterinary preparations;
pharmaceutical and veterinary preparations (medical
purposes); diagnostic preparations and diagnostic reagents;
diagnostic reagents, for medical purposes; diagnostic
reagents kits for medical purposes; in vitro diagnostic
reagents for medical purposes; in vitro diagnostic reagents
kits for medical purposes; diagnostic reagents for
laboratory use for medical purposes; diagnostic reagents
kits for laboratory use for medical or veterinary purposes;
in vitro diagnostic reagents for medical purposes for
determining allergies; in vitro diagnostic reagents kits for
determining allergies. Medical apparatus; diagnostic imaging apparatus for medical
purposes; apparatus for use in medical analysis; measuring
apparatus for medical purposes; apparatus for measuring,
inspecting and analyzing reacted specimen with diagnostic
reagents; medical apparatus for immunoassay (medical use);
mobile medical apparatus for enzyme-linked immunosorbent
assay (medical use); medical apparatus for measuring
specific IgE antibodies.
